New tests launched in March
New Tests
In March 2023, Mayo Clinic Laboratories announced twenty nine new tests along with numerous reference value changes, obsolete tests, and algorithm changes.
The new tests that launched in March 2023 by Mayo Clinic Laboratories:
FMPP2 | Myocarditis/Pericarditis Panel
MCRNA | Chlamydia trachomatis, Miscellaneous Sites, Nucleic Acid Amplification, Varies
This test is for detecting Chlamydia trachomatis in non-US Food and Drug Administration-approved specimen types.
This test is not intended for use in medico-legal applications.
This test is not useful for the detection of Chlamydia pneumoniae or other Chlamydiaspecies.
CBL | Blastomyces Antibody Immunodiffusion, Spinal Fluid
This test is for detecting antibodies in spinal fluid specimens from patients with blastomycosis.
SBL | Blastomyces Antibody Immunodiffusion, Serum
This test is for detecting antibodies in serum specimens from patients with blastomycosis.
HICBL | Histoplasma/Blastomyces Panel, Spinal Fluid
This test is for aiding in the diagnosis of Histoplasma meningitis.
Detecting antibodies in patients with blastomycosis.
CRT2F | Creatinine, 24 Hour, Urine
This test is for normalizing urinary analytes to account for the variation in urinary concentration.
CRTFR | Creatinine, Random, Urine
This test is for normalizing urinary analytes to account for the variation in urinary concentrations between individuals when using random urine collections.
HIBAG | Histoplasma and Blastomyces Antigen, Enzyme Immunoassay, Serum
This test is for monitoring antigen levels following initiation of antifungal treatment.
ALPSG | Autoimmune Lymphoproliferative Syndrome (ALPS) Gene Panel, Varies
This test is for providing a comprehensive genetic evaluation for patients with a personal or family history suggestive of autoimmune lymphoproliferative syndrome (ALPS) or related disorders.
Establishing a diagnosis of ALPS or a related disorder, allowing for appropriate management and surveillance for disease features based on the gene or variant involved.
Identifying variants within genes known to be associated with ALPS or a related disorder, allowing for predictive testing of at-risk family members.
HIESG | Hyper-IgE Syndrome Gene Panel, Varies
This test is for providing a comprehensive genetic evaluation for patients with a personal or family history suggestive of hyper-IgE syndrome (HIES).
Establishing a diagnosis of HIES, allowing for appropriate management and surveillance for disease features based on the gene and/or variant involved.
Identifying variants within genes known to be associated with HIES, allowing for predictive testing of at-risk family members and/or determination of targeted management (anticipatory guidance, management changes, specific therapies).
GATAS | GATA-Binding Protein 2, GATA2, Full Gene Analysis, Next-Generation Sequencing, Varies
This test is for screening family members of patients with confirmed GATA2 deficiency.
Comprehensive evaluation of the GATA2 gene in patients with clinical or immunologicalsymptoms suggestive of GATA-binding protein 2 (GATA2) deficiency.
EBLPD | Epstein Barr Virus (EBV) Susceptibility and Lymphoproliferative Disorders Gene Panel, Varies
This test is providing a comprehensive genetic evaluation for patients with a personal or family history suggestive of Epstein-Barr virus (EBV) susceptibility or a heritable predisposition to lymphoproliferative disease.
Establishing a diagnosis of a hereditary form of EBV susceptibility or a related disorder, allowing for appropriate management and surveillance for disease features based on the gene or variant involved.
Identifying variants within genes known to be associated with heritable EBV susceptibility and/or lymphoproliferative disease, allowing for predictive testing of at-risk family members.
CFTRN | Cystic Fibrosis Transmembrane Conductance Regulator, CFTR, Full Gene Analysis, Varies
This test is for follow-up testing to identify variants in individuals with a clinical diagnosis of cystic fibrosis (CF).
Identifying genetic variants in individuals with atypical presentations of CF (eg, congenital bilateral absence of the vas deferens or pancreatitis).
Identifying genetic variants in individuals where detection rates by targeted variant analysis are low or unknown for their ancestral background.
Identifying patients who may respond to cystic fibrosis transmembrane conductance regulator (CFTR) potentiator therapy.
BTKSG | Bruton Tyrosine Kinase, BTK Full Gene Analysis, Varies
This test is confirming a diagnosis of X-linked agammaglobulinemia in patients with a history of recurrent sinopulmonary infections, profound hypogammaglobulinemia, and less than 1% peripheral B cells, with or without abnormal Bruton tyrosine kinase (BTK) protein expression by flow cytometry.
Evaluating for the presence of BTK variants in family members of affected individuals, including those who do not demonstrate carrier phenotype by BTK flow cytometry.
QFEVR | Q Fever Antibody Screen with Titer Reflex, Serum
This test is for screening for exposure to Coxiella burnetii, the causative agent of Q fever.
This test should not be used as a screening procedure for the general population.
VIRID | Viral Susceptibility, Defects in Intrinsic and Innate Immunity, Gene Panel, Varies
This test is for providing a comprehensive genetic evaluation for patients with a personal or family history suggestive of an inborn error of immunity causing a hereditary form of severe viral susceptibility.
Establishing a diagnosis of hereditary form of viral susceptibility, allowing for appropriate management and surveillance for disease features based on the gene and/or variant involved.
Identifying variants within genes known to be associated with a hereditary form of viral susceptibility, allowing for predictive testing of at-risk family members.
TELDP | Telomere Biology Disorders Gene Panel, Varies
This test is for providing a comprehensive genetic evaluation for patients with a personal or family history suggestive of a telomere biology disorder.
Establishing a diagnosis of a telomere biology disorder, allowing for appropriate management and surveillance for disease features based on the gene and/or variant involved.
Identifying disease-causing variants within genes known to be associated with increased risk for telomere defects, allowing for predictive testing of at-risk family members.
SCCNP | Severe Congenital and Cyclic Neutropenia Gene Panel, Varies
This test is for providing a genetic evaluation for patients with a personal or family history suggestive of severe congenital neutropenia and/or cyclic neutropenia.
Establishing a diagnosis of an inherited congenital neutropenia and, in some cases, allowing for appropriate management and surveillance for disease features based on the gene involved.
IMMAU | Inborn Errors of Immunity with Immune Dysregulation and Autoimmunity Gene Panel, Varies
This test is for providing a comprehensive genetic evaluation for patients with a personal or family history suggestive of an inborn error of immunity (IEI) associated with immune dysregulation or autoimmunity.
Establishing a diagnosis of an IEI, allowing for appropriate management and surveillance for disease features based on the gene and/or variant involved.
Identifying variants within genes known to be associated with immune dysregulation or autoimmunity, allowing for predictive testing of at-risk family members.
HPANP | Hereditary Pancreatitis Gene Panel, Varies
This test is for confirming a suspected clinical diagnosis of familial or hereditary pancreatitis in patients with chronic pancreatitis.
Identifying gene variants contributing to pancreatitis in an individual or family.
Identifying gene variants to allow for predictive and diagnostic testing in family members.
HLHGP | Primary Hemophagocytic Lymphohistiocytosis Gene Panel, Varies
This test is for providing a comprehensive genetic evaluation for patients with a personal or family history suggestive of familial hemophagocytic lymphohistiocytosis (F-HLH).
Establishing a diagnosis of F-HLH, allowing for appropriate management and surveillance for disease features based on the gene and/or variant involved.
Identifying variants within genes known to be associated with F-HLH, allowing for predictive testing of at-risk family members.
VZIKU | Zika Virus, PCR, Molecular Detection, Random, Urine
This test is for qualitative detection of Zika virus RNA in paired urine and serum from individuals meeting the Centers of Disease Control and Prevention Zika virus clinical or epidemiologic criteria.
VZIKS | Zika Virus, PCR, Molecular Detection, Serum
This test is for qualitative detection of Zika virus RNA in serum from individuals meeting the Centers of Disease Control and Prevention Zika virus clinical or epidemiologic criteria.
FHCCF | THC Confirmation, MS, SP
FMARX | THC, MS, WB/SP Rfx
This test is for confirming the presence or absence of minimal residual disease in patients with known chronic lymphocytic leukemia who are either post-chemo/immunotherapy or post-bone marrow transplantation.
CHLG | Chlamydia IgG, Immunofluorescence, Serum
This test is for assessing IgG antibody levels to aid in the clinical diagnosis of Chlamydia pneumoniae or Chlamydia psittaci infections.
CHLM | Chlamydia IgM, Immunofluorescence, Serum
This test is for assessing IgM antibody levels to aid in the clinical diagnosis of Chlamydia pneumoniae or Chlamydia psittaci infections.
CHLAP | Chlamydia IgM and IgG Panel, Immunofluorescence, Serum
This test is for aiding in the clinical diagnosis of Chlamydia pneumoniae or Chlamydia psittaci infection.
In addition to these tests, the department also announced several test changes. Click the links below to view test changes announced by Mayo Clinic Laboratories: